t98g Search Results


t98g  (ATCC)
99
ATCC t98g
T98g, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/t98g/product/ATCC
Average 99 stars, based on 1 article reviews
t98g - by Bioz Stars, 2026-04
99/100 stars
  Buy from Supplier

90
CLS Cell Lines Service GmbH t98g
T98g, supplied by CLS Cell Lines Service GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/t98g/product/CLS Cell Lines Service GmbH
Average 90 stars, based on 1 article reviews
t98g - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

93
Santa Cruz Biotechnology t98g cell lysate
Figure 5. IGFBP-2 protein expression in tumor cells derived from neu transgenic mice. IGFBP-2 monoclonal antibody staining of MMC cells. A, secondary antibody alone. B, IGFBP-2 protein expression. Magnification, 400. Black bar, 20 mm. C, top, Western blot of 10 Ag SKBR3, MCF-7, <t>T98G,</t> MMC, and neu transgenic mouse spleen lysate. Arrow, 40-kDa level of molecular weight (MW) marker (36-kDa IGFBP-2). Bottom, h-actin expression in 10 Ag of the same lysates.
T98g Cell Lysate, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/t98g cell lysate/product/Santa Cruz Biotechnology
Average 93 stars, based on 1 article reviews
t98g cell lysate - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier

90
Innovative Research Inc t98g right cells
Figure 5. IGFBP-2 protein expression in tumor cells derived from neu transgenic mice. IGFBP-2 monoclonal antibody staining of MMC cells. A, secondary antibody alone. B, IGFBP-2 protein expression. Magnification, 400. Black bar, 20 mm. C, top, Western blot of 10 Ag SKBR3, MCF-7, <t>T98G,</t> MMC, and neu transgenic mouse spleen lysate. Arrow, 40-kDa level of molecular weight (MW) marker (36-kDa IGFBP-2). Bottom, h-actin expression in 10 Ag of the same lysates.
T98g Right Cells, supplied by Innovative Research Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/t98g right cells/product/Innovative Research Inc
Average 90 stars, based on 1 article reviews
t98g right cells - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
Tsang MD Inc cell lines
Figure 5. IGFBP-2 protein expression in tumor cells derived from neu transgenic mice. IGFBP-2 monoclonal antibody staining of MMC cells. A, secondary antibody alone. B, IGFBP-2 protein expression. Magnification, 400. Black bar, 20 mm. C, top, Western blot of 10 Ag SKBR3, MCF-7, <t>T98G,</t> MMC, and neu transgenic mouse spleen lysate. Arrow, 40-kDa level of molecular weight (MW) marker (36-kDa IGFBP-2). Bottom, h-actin expression in 10 Ag of the same lysates.
Cell Lines, supplied by Tsang MD Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cell lines/product/Tsang MD Inc
Average 90 stars, based on 1 article reviews
cell lines - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
GenScript corporation ln229 and t98g cells overexpressing cldn4
CLND4 promotes malignancy in glioma cells. A. Expression levels (mRNA) of CLDN4 in normal tissues (n=5) and glioma tissues (n=156); data derived from TCGA database. B. Representative images of immunohistochemical staining for CLDN4 in para-carcinomatous tissues (n=15), early-stage glioma tissues (stage I-II, n=15), and late-stage glioma tissues (stage III-IV, n=15); scale bar =50 μm. C. Kaplan-Meier survival curve for high and low expression of CLDN4 in glioma patients (n=513); data from TCGA database. D. Western blotting for CLDN4 in <t>LN229/T98G</t> cells transfected with empty vector or a CLDN4-overexpression vector. E. Cell proliferation assay (CCK-8 assay) for LN229/T98G cells transfected with empty vector or CLDN4-overexpression vector. T98G, P<0.05, 72 hours; LN229, P<0.01, 72 hours. F. Cell migration assay (Transwell assay) for LN229/T98G cells transfected with empty vector or CLDN4-overexpression vector; scale bar =100 μm. G. Colony formation assay for LN229/T98G cells transfected with empty vector or CLDN4-overexpression vector.
Ln229 And T98g Cells Overexpressing Cldn4, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ln229 and t98g cells overexpressing cldn4/product/GenScript corporation
Average 90 stars, based on 1 article reviews
ln229 and t98g cells overexpressing cldn4 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
STEMCELL Technologies Inc u87mg, t98g, ts-603, 13.0302 neurospheres
CLND4 promotes malignancy in glioma cells. A. Expression levels (mRNA) of CLDN4 in normal tissues (n=5) and glioma tissues (n=156); data derived from TCGA database. B. Representative images of immunohistochemical staining for CLDN4 in para-carcinomatous tissues (n=15), early-stage glioma tissues (stage I-II, n=15), and late-stage glioma tissues (stage III-IV, n=15); scale bar =50 μm. C. Kaplan-Meier survival curve for high and low expression of CLDN4 in glioma patients (n=513); data from TCGA database. D. Western blotting for CLDN4 in <t>LN229/T98G</t> cells transfected with empty vector or a CLDN4-overexpression vector. E. Cell proliferation assay (CCK-8 assay) for LN229/T98G cells transfected with empty vector or CLDN4-overexpression vector. T98G, P<0.05, 72 hours; LN229, P<0.01, 72 hours. F. Cell migration assay (Transwell assay) for LN229/T98G cells transfected with empty vector or CLDN4-overexpression vector; scale bar =100 μm. G. Colony formation assay for LN229/T98G cells transfected with empty vector or CLDN4-overexpression vector.
U87mg, T98g, Ts 603, 13.0302 Neurospheres, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/u87mg, t98g, ts-603, 13.0302 neurospheres/product/STEMCELL Technologies Inc
Average 90 stars, based on 1 article reviews
u87mg, t98g, ts-603, 13.0302 neurospheres - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
Elabscience Biotechnology t98g
CLND4 promotes malignancy in glioma cells. A. Expression levels (mRNA) of CLDN4 in normal tissues (n=5) and glioma tissues (n=156); data derived from TCGA database. B. Representative images of immunohistochemical staining for CLDN4 in para-carcinomatous tissues (n=15), early-stage glioma tissues (stage I-II, n=15), and late-stage glioma tissues (stage III-IV, n=15); scale bar =50 μm. C. Kaplan-Meier survival curve for high and low expression of CLDN4 in glioma patients (n=513); data from TCGA database. D. Western blotting for CLDN4 in <t>LN229/T98G</t> cells transfected with empty vector or a CLDN4-overexpression vector. E. Cell proliferation assay (CCK-8 assay) for LN229/T98G cells transfected with empty vector or CLDN4-overexpression vector. T98G, P<0.05, 72 hours; LN229, P<0.01, 72 hours. F. Cell migration assay (Transwell assay) for LN229/T98G cells transfected with empty vector or CLDN4-overexpression vector; scale bar =100 μm. G. Colony formation assay for LN229/T98G cells transfected with empty vector or CLDN4-overexpression vector.
T98g, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/t98g/product/Elabscience Biotechnology
Average 90 stars, based on 1 article reviews
t98g - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
iCell Gene Therapeutics human glioblastoma cells t98g
CLND4 promotes malignancy in glioma cells. A. Expression levels (mRNA) of CLDN4 in normal tissues (n=5) and glioma tissues (n=156); data derived from TCGA database. B. Representative images of immunohistochemical staining for CLDN4 in para-carcinomatous tissues (n=15), early-stage glioma tissues (stage I-II, n=15), and late-stage glioma tissues (stage III-IV, n=15); scale bar =50 μm. C. Kaplan-Meier survival curve for high and low expression of CLDN4 in glioma patients (n=513); data from TCGA database. D. Western blotting for CLDN4 in <t>LN229/T98G</t> cells transfected with empty vector or a CLDN4-overexpression vector. E. Cell proliferation assay (CCK-8 assay) for LN229/T98G cells transfected with empty vector or CLDN4-overexpression vector. T98G, P<0.05, 72 hours; LN229, P<0.01, 72 hours. F. Cell migration assay (Transwell assay) for LN229/T98G cells transfected with empty vector or CLDN4-overexpression vector; scale bar =100 μm. G. Colony formation assay for LN229/T98G cells transfected with empty vector or CLDN4-overexpression vector.
Human Glioblastoma Cells T98g, supplied by iCell Gene Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human glioblastoma cells t98g/product/iCell Gene Therapeutics
Average 90 stars, based on 1 article reviews
human glioblastoma cells t98g - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
BioResource International Inc t98g cells
CLND4 promotes malignancy in glioma cells. A. Expression levels (mRNA) of CLDN4 in normal tissues (n=5) and glioma tissues (n=156); data derived from TCGA database. B. Representative images of immunohistochemical staining for CLDN4 in para-carcinomatous tissues (n=15), early-stage glioma tissues (stage I-II, n=15), and late-stage glioma tissues (stage III-IV, n=15); scale bar =50 μm. C. Kaplan-Meier survival curve for high and low expression of CLDN4 in glioma patients (n=513); data from TCGA database. D. Western blotting for CLDN4 in <t>LN229/T98G</t> cells transfected with empty vector or a CLDN4-overexpression vector. E. Cell proliferation assay (CCK-8 assay) for LN229/T98G cells transfected with empty vector or CLDN4-overexpression vector. T98G, P<0.05, 72 hours; LN229, P<0.01, 72 hours. F. Cell migration assay (Transwell assay) for LN229/T98G cells transfected with empty vector or CLDN4-overexpression vector; scale bar =100 μm. G. Colony formation assay for LN229/T98G cells transfected with empty vector or CLDN4-overexpression vector.
T98g Cells, supplied by BioResource International Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/t98g cells/product/BioResource International Inc
Average 90 stars, based on 1 article reviews
t98g cells - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
JCRB Cell Bank human glioblastoma a172 cells
CLND4 promotes malignancy in glioma cells. A. Expression levels (mRNA) of CLDN4 in normal tissues (n=5) and glioma tissues (n=156); data derived from TCGA database. B. Representative images of immunohistochemical staining for CLDN4 in para-carcinomatous tissues (n=15), early-stage glioma tissues (stage I-II, n=15), and late-stage glioma tissues (stage III-IV, n=15); scale bar =50 μm. C. Kaplan-Meier survival curve for high and low expression of CLDN4 in glioma patients (n=513); data from TCGA database. D. Western blotting for CLDN4 in <t>LN229/T98G</t> cells transfected with empty vector or a CLDN4-overexpression vector. E. Cell proliferation assay (CCK-8 assay) for LN229/T98G cells transfected with empty vector or CLDN4-overexpression vector. T98G, P<0.05, 72 hours; LN229, P<0.01, 72 hours. F. Cell migration assay (Transwell assay) for LN229/T98G cells transfected with empty vector or CLDN4-overexpression vector; scale bar =100 μm. G. Colony formation assay for LN229/T98G cells transfected with empty vector or CLDN4-overexpression vector.
Human Glioblastoma A172 Cells, supplied by JCRB Cell Bank, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human glioblastoma a172 cells/product/JCRB Cell Bank
Average 90 stars, based on 1 article reviews
human glioblastoma a172 cells - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
Interlab Inc t98g glioma cells
Effect of rALR treatment on H 2 O 2 -induced ROS levels on glioma cells. Human <t>T98G</t> glioma cells, treated with H 2 O 2 , were incubated with different concentrations of rALR (1–100 ng/ml). The means±S.D. of six triplicate independent experiments are shown
T98g Glioma Cells, supplied by Interlab Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/t98g glioma cells/product/Interlab Inc
Average 90 stars, based on 1 article reviews
t98g glioma cells - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

Image Search Results


Figure 5. IGFBP-2 protein expression in tumor cells derived from neu transgenic mice. IGFBP-2 monoclonal antibody staining of MMC cells. A, secondary antibody alone. B, IGFBP-2 protein expression. Magnification, 400. Black bar, 20 mm. C, top, Western blot of 10 Ag SKBR3, MCF-7, T98G, MMC, and neu transgenic mouse spleen lysate. Arrow, 40-kDa level of molecular weight (MW) marker (36-kDa IGFBP-2). Bottom, h-actin expression in 10 Ag of the same lysates.

Journal: Cancer Research

Article Title: Insulin-like Growth Factor–Binding Protein-2 Is a Target for the Immunomodulation of Breast Cancer

doi: 10.1158/0008-5472.can-07-5891

Figure Lengend Snippet: Figure 5. IGFBP-2 protein expression in tumor cells derived from neu transgenic mice. IGFBP-2 monoclonal antibody staining of MMC cells. A, secondary antibody alone. B, IGFBP-2 protein expression. Magnification, 400. Black bar, 20 mm. C, top, Western blot of 10 Ag SKBR3, MCF-7, T98G, MMC, and neu transgenic mouse spleen lysate. Arrow, 40-kDa level of molecular weight (MW) marker (36-kDa IGFBP-2). Bottom, h-actin expression in 10 Ag of the same lysates.

Article Snippet: Commercially provided T98G cell lysate (Santa Cruz Biotechnology) was used as a positive control.

Techniques: Expressing, Derivative Assay, Transgenic Assay, Staining, Western Blot, Molecular Weight, Marker

CLND4 promotes malignancy in glioma cells. A. Expression levels (mRNA) of CLDN4 in normal tissues (n=5) and glioma tissues (n=156); data derived from TCGA database. B. Representative images of immunohistochemical staining for CLDN4 in para-carcinomatous tissues (n=15), early-stage glioma tissues (stage I-II, n=15), and late-stage glioma tissues (stage III-IV, n=15); scale bar =50 μm. C. Kaplan-Meier survival curve for high and low expression of CLDN4 in glioma patients (n=513); data from TCGA database. D. Western blotting for CLDN4 in LN229/T98G cells transfected with empty vector or a CLDN4-overexpression vector. E. Cell proliferation assay (CCK-8 assay) for LN229/T98G cells transfected with empty vector or CLDN4-overexpression vector. T98G, P<0.05, 72 hours; LN229, P<0.01, 72 hours. F. Cell migration assay (Transwell assay) for LN229/T98G cells transfected with empty vector or CLDN4-overexpression vector; scale bar =100 μm. G. Colony formation assay for LN229/T98G cells transfected with empty vector or CLDN4-overexpression vector.

Journal: American Journal of Cancer Research

Article Title: Claudin 4 enhances the malignancy of glioma cells via NNAT/Wnt signaling

doi:

Figure Lengend Snippet: CLND4 promotes malignancy in glioma cells. A. Expression levels (mRNA) of CLDN4 in normal tissues (n=5) and glioma tissues (n=156); data derived from TCGA database. B. Representative images of immunohistochemical staining for CLDN4 in para-carcinomatous tissues (n=15), early-stage glioma tissues (stage I-II, n=15), and late-stage glioma tissues (stage III-IV, n=15); scale bar =50 μm. C. Kaplan-Meier survival curve for high and low expression of CLDN4 in glioma patients (n=513); data from TCGA database. D. Western blotting for CLDN4 in LN229/T98G cells transfected with empty vector or a CLDN4-overexpression vector. E. Cell proliferation assay (CCK-8 assay) for LN229/T98G cells transfected with empty vector or CLDN4-overexpression vector. T98G, P<0.05, 72 hours; LN229, P<0.01, 72 hours. F. Cell migration assay (Transwell assay) for LN229/T98G cells transfected with empty vector or CLDN4-overexpression vector; scale bar =100 μm. G. Colony formation assay for LN229/T98G cells transfected with empty vector or CLDN4-overexpression vector.

Article Snippet: Transfected LN229 and T98G cells overexpressing CLDN4 were obtained from GenScript ProBio (China); the same cells transfected with the empty vector (without the CLDN4 gene) were also obtained from the same source.

Techniques: Expressing, Derivative Assay, Immunohistochemical staining, Staining, Western Blot, Transfection, Plasmid Preparation, Over Expression, Proliferation Assay, CCK-8 Assay, Cell Migration Assay, Transwell Assay, Colony Assay

CLDN4-stimulated NNAT upregulation. A. The top 30 upregulated genes in patients with gliomas that had high CLDN4 expression levels as compared to those with gliomas having low CLDN4 expression levels; data derived from TCGA database (n=513). B. Western blotting for CLDN4 and NNAT in LN229/T98G cells transfected with empty vector or CLDN4-overexpression vector. C. Cell proliferation assays for LN229/T98G cells transfected with empty vector or CLDN4-overexpression vector treated with scramble or NNAT siRNAs. LN229, vector vs vector + siRNA, P>0.05, OE vs OE + siRNA, P<0.05, 72 hours; T98G, vector vs vector + siRNA, P>0.05, OE vs OE + siRNA, P<0.01, 72 hours. D. Cell migration assay for LN229/T98G cells transfected with empty vector or CLDN4-overexpression vector treated with scramble or NNAT siRNAs. E. Colony formation assays for LN229/T98G cells transfected with empty vector or CLDN4-overexpression vector treated with scramble or NNAT siRNAs. F. Representative images of immunohistochemical staining for CLND4 in early-stage glioma tissues (stage I-II, n=15) and late-stage glioma tissues (stage III-IV, n=15); scale bar =100 μm.

Journal: American Journal of Cancer Research

Article Title: Claudin 4 enhances the malignancy of glioma cells via NNAT/Wnt signaling

doi:

Figure Lengend Snippet: CLDN4-stimulated NNAT upregulation. A. The top 30 upregulated genes in patients with gliomas that had high CLDN4 expression levels as compared to those with gliomas having low CLDN4 expression levels; data derived from TCGA database (n=513). B. Western blotting for CLDN4 and NNAT in LN229/T98G cells transfected with empty vector or CLDN4-overexpression vector. C. Cell proliferation assays for LN229/T98G cells transfected with empty vector or CLDN4-overexpression vector treated with scramble or NNAT siRNAs. LN229, vector vs vector + siRNA, P>0.05, OE vs OE + siRNA, P<0.05, 72 hours; T98G, vector vs vector + siRNA, P>0.05, OE vs OE + siRNA, P<0.01, 72 hours. D. Cell migration assay for LN229/T98G cells transfected with empty vector or CLDN4-overexpression vector treated with scramble or NNAT siRNAs. E. Colony formation assays for LN229/T98G cells transfected with empty vector or CLDN4-overexpression vector treated with scramble or NNAT siRNAs. F. Representative images of immunohistochemical staining for CLND4 in early-stage glioma tissues (stage I-II, n=15) and late-stage glioma tissues (stage III-IV, n=15); scale bar =100 μm.

Article Snippet: Transfected LN229 and T98G cells overexpressing CLDN4 were obtained from GenScript ProBio (China); the same cells transfected with the empty vector (without the CLDN4 gene) were also obtained from the same source.

Techniques: Expressing, Derivative Assay, Western Blot, Transfection, Plasmid Preparation, Over Expression, Cell Migration Assay, Immunohistochemical staining, Staining

The CLDN4/NNAT axis modulates glioma progression through Wnt signaling. (A and B) The results of the KEGG enrichment analysis for the major signaling pathways involved in glioma progression in 513 glioma patients divided into CLDN4-high/low (A) or NNAT-high/low (B) groups. (C) Western blotting for Wnt1, Wnt2, and Wnt3A in LN229 cells transfected with empty vector or CLDN4-overexpression vector. (D) Western blotting for Wnt3A in LN229/T98G cells transfected with empty vector or CLDN4-overexpression vector treated with scramble or NNAT siRNAs. (E) Cell proliferation assays for LN229/T98G cells transfected with empty vector or CLDN4-overexpression vector treated with PBS or pyrvinium pamoate (10 nM). LN229, vector vs vector + PP, P>0.05, OE vs OE + PP, P<0.05, 72 hours; T98G, vector vs vector + PP, P>0.05, OE vs OE + PP, P<0.05, 72 hours. (F) Cell migration assays for LN229/T98G cells transfected with empty vector or CLDN4-overexpression vector treated with PBS or pyrvinium pamoate (10 nM). (G) Colony formation assays for LN229/T98G cells transfected with empty vector or CLDN4-overexpression vector treated with PBS or pyrvinium pamoate (10 nM).

Journal: American Journal of Cancer Research

Article Title: Claudin 4 enhances the malignancy of glioma cells via NNAT/Wnt signaling

doi:

Figure Lengend Snippet: The CLDN4/NNAT axis modulates glioma progression through Wnt signaling. (A and B) The results of the KEGG enrichment analysis for the major signaling pathways involved in glioma progression in 513 glioma patients divided into CLDN4-high/low (A) or NNAT-high/low (B) groups. (C) Western blotting for Wnt1, Wnt2, and Wnt3A in LN229 cells transfected with empty vector or CLDN4-overexpression vector. (D) Western blotting for Wnt3A in LN229/T98G cells transfected with empty vector or CLDN4-overexpression vector treated with scramble or NNAT siRNAs. (E) Cell proliferation assays for LN229/T98G cells transfected with empty vector or CLDN4-overexpression vector treated with PBS or pyrvinium pamoate (10 nM). LN229, vector vs vector + PP, P>0.05, OE vs OE + PP, P<0.05, 72 hours; T98G, vector vs vector + PP, P>0.05, OE vs OE + PP, P<0.05, 72 hours. (F) Cell migration assays for LN229/T98G cells transfected with empty vector or CLDN4-overexpression vector treated with PBS or pyrvinium pamoate (10 nM). (G) Colony formation assays for LN229/T98G cells transfected with empty vector or CLDN4-overexpression vector treated with PBS or pyrvinium pamoate (10 nM).

Article Snippet: Transfected LN229 and T98G cells overexpressing CLDN4 were obtained from GenScript ProBio (China); the same cells transfected with the empty vector (without the CLDN4 gene) were also obtained from the same source.

Techniques: Protein-Protein interactions, Western Blot, Transfection, Plasmid Preparation, Over Expression, Migration

CLDN4 facilitates glioma growth in vivo. A. Western blotting for CLDN4 in primary glioma cells derived from 6 patients. B. Representative images of PDOs derived from CLDN4-high and -low glioma tissues; scale bar =50 μm. C. Western blotting for Wnt3A and NNAT in PDOs derived from CLDN4-high and -low glioma tissues. D. Representative images for immunofluorescence staining for Ki67 in PDOs derived from CLDN4-high and -low glioma tissues; scale bar =50 μm. E. Tumor volumes of subcutaneous tumors formed by LN229 cells transfected with empty vector or CLDN4-overexpression vector (n=5 in each group). F. Kaplan-Meier survival curve for mice with tumors formed by LN229 cells transfected with empty vector or CLDN4-overexpression vector (n=5 in each group).

Journal: American Journal of Cancer Research

Article Title: Claudin 4 enhances the malignancy of glioma cells via NNAT/Wnt signaling

doi:

Figure Lengend Snippet: CLDN4 facilitates glioma growth in vivo. A. Western blotting for CLDN4 in primary glioma cells derived from 6 patients. B. Representative images of PDOs derived from CLDN4-high and -low glioma tissues; scale bar =50 μm. C. Western blotting for Wnt3A and NNAT in PDOs derived from CLDN4-high and -low glioma tissues. D. Representative images for immunofluorescence staining for Ki67 in PDOs derived from CLDN4-high and -low glioma tissues; scale bar =50 μm. E. Tumor volumes of subcutaneous tumors formed by LN229 cells transfected with empty vector or CLDN4-overexpression vector (n=5 in each group). F. Kaplan-Meier survival curve for mice with tumors formed by LN229 cells transfected with empty vector or CLDN4-overexpression vector (n=5 in each group).

Article Snippet: Transfected LN229 and T98G cells overexpressing CLDN4 were obtained from GenScript ProBio (China); the same cells transfected with the empty vector (without the CLDN4 gene) were also obtained from the same source.

Techniques: In Vivo, Western Blot, Derivative Assay, Immunofluorescence, Staining, Transfection, Plasmid Preparation, Over Expression

Effect of rALR treatment on H 2 O 2 -induced ROS levels on glioma cells. Human T98G glioma cells, treated with H 2 O 2 , were incubated with different concentrations of rALR (1–100 ng/ml). The means±S.D. of six triplicate independent experiments are shown

Journal: Cell Death & Disease

Article Title: Decreased expression of the Augmenter of Liver Regeneration results in increased apoptosis and oxidative damage in human-derived glioma cells

doi: 10.1038/cddis.2012.25

Figure Lengend Snippet: Effect of rALR treatment on H 2 O 2 -induced ROS levels on glioma cells. Human T98G glioma cells, treated with H 2 O 2 , were incubated with different concentrations of rALR (1–100 ng/ml). The means±S.D. of six triplicate independent experiments are shown

Article Snippet: Human-derived T98G glioma cells (Interlab Cell Line Collection, Genoa, Italy) were cultured in Dulbecco's modified Eagle's medium (DMEM) (Sigma-Aldrich) supplemented with 10% (v/v) inactivated FBS (PAA Laboratories GmbH, Pasching, Austria), 2 mM L -glutamine (Sigma-Aldrich), 100 μ g/ml penicillin and 100 μ g/ml streptomycin (Sigma-Aldrich,) at 37°C in 5% CO 2 .

Techniques: Incubation

Effect of siRNA/ALR treatment on ALR expression. ALR expression in siRNA/ALR-treated and control human T98G glioma cells, determined using western blot analysis ( a ) and confocal microscopy ( b , green colour), are reported. The data shown are means±S.D. from five independent experiments

Journal: Cell Death & Disease

Article Title: Decreased expression of the Augmenter of Liver Regeneration results in increased apoptosis and oxidative damage in human-derived glioma cells

doi: 10.1038/cddis.2012.25

Figure Lengend Snippet: Effect of siRNA/ALR treatment on ALR expression. ALR expression in siRNA/ALR-treated and control human T98G glioma cells, determined using western blot analysis ( a ) and confocal microscopy ( b , green colour), are reported. The data shown are means±S.D. from five independent experiments

Article Snippet: Human-derived T98G glioma cells (Interlab Cell Line Collection, Genoa, Italy) were cultured in Dulbecco's modified Eagle's medium (DMEM) (Sigma-Aldrich) supplemented with 10% (v/v) inactivated FBS (PAA Laboratories GmbH, Pasching, Austria), 2 mM L -glutamine (Sigma-Aldrich), 100 μ g/ml penicillin and 100 μ g/ml streptomycin (Sigma-Aldrich,) at 37°C in 5% CO 2 .

Techniques: Expressing, Western Blot, Confocal Microscopy

Effect of siRNA/ALR treatment on clusterin expression. Clusterin expression in siRNA/ALR-treated and control human T98G glioma cells, determined using western blot analysis ( a , upper right) and confocal microscopy ( b , green colour), are reported. The data shown are means±S.D. from three independent experiments

Journal: Cell Death & Disease

Article Title: Decreased expression of the Augmenter of Liver Regeneration results in increased apoptosis and oxidative damage in human-derived glioma cells

doi: 10.1038/cddis.2012.25

Figure Lengend Snippet: Effect of siRNA/ALR treatment on clusterin expression. Clusterin expression in siRNA/ALR-treated and control human T98G glioma cells, determined using western blot analysis ( a , upper right) and confocal microscopy ( b , green colour), are reported. The data shown are means±S.D. from three independent experiments

Article Snippet: Human-derived T98G glioma cells (Interlab Cell Line Collection, Genoa, Italy) were cultured in Dulbecco's modified Eagle's medium (DMEM) (Sigma-Aldrich) supplemented with 10% (v/v) inactivated FBS (PAA Laboratories GmbH, Pasching, Austria), 2 mM L -glutamine (Sigma-Aldrich), 100 μ g/ml penicillin and 100 μ g/ml streptomycin (Sigma-Aldrich,) at 37°C in 5% CO 2 .

Techniques: Expressing, Western Blot, Confocal Microscopy

Effect of siRNA/ALR treatment on apoptotic gene expression. bcl-2 and bax ( a ), caspase-9 ( b ) and activated caspase-3 ( c ) expression in siRNA/ALR-treated and control human T98G glioma cells, determined using western blot analysis, are reported. The data shown are means±S.D. from five independent experiments

Journal: Cell Death & Disease

Article Title: Decreased expression of the Augmenter of Liver Regeneration results in increased apoptosis and oxidative damage in human-derived glioma cells

doi: 10.1038/cddis.2012.25

Figure Lengend Snippet: Effect of siRNA/ALR treatment on apoptotic gene expression. bcl-2 and bax ( a ), caspase-9 ( b ) and activated caspase-3 ( c ) expression in siRNA/ALR-treated and control human T98G glioma cells, determined using western blot analysis, are reported. The data shown are means±S.D. from five independent experiments

Article Snippet: Human-derived T98G glioma cells (Interlab Cell Line Collection, Genoa, Italy) were cultured in Dulbecco's modified Eagle's medium (DMEM) (Sigma-Aldrich) supplemented with 10% (v/v) inactivated FBS (PAA Laboratories GmbH, Pasching, Austria), 2 mM L -glutamine (Sigma-Aldrich), 100 μ g/ml penicillin and 100 μ g/ml streptomycin (Sigma-Aldrich,) at 37°C in 5% CO 2 .

Techniques: Expressing, Western Blot